Description
Release form
effervescent tablets.
Packing
80 pcs.
Pharmacological action
Drug for the treatment of nephrolithiasis. Blemaren dissolves and prevents the formation of uric acid stones by alkalizing urine to pH 6.6 6.8 (when urine pH is in the range of 6.6 6.8, the dissolution of uric acid salts increases significantly).
Also reduces calcium excretion, improves the solubility of calcium oxalate in urine, inhibits the formation of crystals and, therefore, prevents the formation of calcium-oxalate stones.
Indications
Prevention of the formation and dissolution of uric acid and calcium oxalate stones.
Dissolution of mixed urate-oxalate stones (with an oxalate content <25%). Alkalization of urine in individuals receiving cytostatics or drugs that increase uric acid excretion. Symptomatic treatment of porphyria of the skin. Contraindications Acute and chronic renal failure. Metabolic alkalosis. Urinary tract infections caused by microorganisms that break down urea. urine pH above 7. The need to follow a strict salt-free diet (for example, with severe forms of arterial hypertension). Hypersensitivity to the drug. Use during pregnancy and lactation There are no safety data on the use of Blemaren during pregnancy and lactation, and therefore it is not recommended to use the drug during these periods. Special instructions The average daily dose (4 effervescent tablets) contains about 1.5 mg of potassium and 0.9 g of sodium, which should be considered when prescribing the drug to patients on a diet with a restriction of salt intake. The drug can be used for chronic renal failure, not accompanied by a delay in potassium ions. Prescribing the drug to patients with diabetes is possible. When dissolving uric acid stones, the daily dose should not be exceeded, since when the pH rises above 7.0, phosphates precipitate on uric acid crystals, which prevents their further dissolution. During treatment, you should limit the intake of foods rich in proteins and purine bases, as well as ensure sufficient fluid intake (not <1.5-2 l). Composition 1 tablet contains: Active substances: citric acid – 1.197 g of potassium bicarbonate – 967.5 mg sodium citrate – 835.5 mg. Excipients: lactose monohydrate – 115 mg, mannitol – 105 mg, adipic acid – 35 mg, macrogol 6000 – 100 mg, sodium saccharin – 10 mg, lemon flavor – 35 mg. Dosing and Administration Before oral administration, effervescent tablets are dissolved in 200 ml of liquid (tea, fruit juices or alkaline mineral water). The daily dose is 2-6 tablets. The daily dose is evenly distributed throughout the day and is taken after meals. The dose is considered to be correctly selected if the urine pH during the day is in the range of 6.2 -7 – for dissolving uric acid stones 7.5 – 8.5 – for dissolving cystine stones 7.2-7.5 – for treating porphyria at least 7.0 – in the treatment of cytostatics. If the urine pH is lower than indicated, the dose must be increased, if higher, then reduced. The duration of treatment is 4-6 months. Efficiency control (determination of urine pH) is carried out 3 times / day, before taking each single dose with indicator paper. The resulting color on paper is compared for 2 minutes with the scale and the resulting value is entered in the control calendar. In the presence of cystine stones and the treatment of porphyria, special indicator paper with a pH value of 7.2 to 9.7 should be used to monitor effectiveness. Side effects Possible: allergic reactions, edema (sodium retention), metabolic alkalosis, dyspepsia. Drug interaction With simultaneous use of blemaren and preparations containing citrates and aluminum, an increase in aluminum absorption is possible, therefore, such preparations should be taken at least 2 hours before or after taking blemaren. The composition of the drug includes potassium, so with the simultaneous use of Blemaren and cardiac glycosides, the pharmacological effect of the latter may be weakened. Some antihypertensive drugs (e.g. aldosterone antagonists, potassium-sparing diuretics, ACE inhibitors), NSAIDs, and analgesics may decrease potassium excretion from the body. The question of the possibility of simultaneous use of Blemaren and the above medicines is decided by the doctor individually. Overdose Data on overdose with Blemaren is not provided. Storage conditions Keep out of the reach and sight of children at temperatures not exceeding 25 ° C. Protect from moisture after opening! Shelf life 2 years. Active ingredient citric acid, potassium bicarbonate, Sodium citrate Terms and conditions prescription dosage form tablets soluble Prescription Prescription ff18 srdlfpp18 prescription 69 prd28 prd18frd18 Prescribing Prescribing For adults as prescribed by a doctor
